Using performance-based risk-sharing arrangements to address uncertainty in indication-based pricing

Journal of Managed Care and Specialty Pharmacy

Volumn 23, Issue 10, 2017, Pages 1010-1015

  Yeung, Kai ^a   Li, Meng ^a   Carlson, Josh J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; CASE STUDY; CONTRACT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FINANCIAL MANAGEMENT; HUMAN; INDICATION BASED PRICING; METASTATIC BREAST CANCER; QUALITY ADJUSTED LIFE YEAR; RISK MANAGEMENT; STOMACH CANCER; UNCERTAINTY; BREAST TUMOR; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; OBSERVATIONAL STUDY; RISK;

BREAST NEOPLASMS; COMMERCE; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RISK; TRASTUZUMAB; UNCERTAINTY;

EID: 85029892627     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2017.23.10.1010     Document Type: Article

References (33)

1. Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014; 312(16):1629-30
2. Pearson SD, Dreitlein B, Henshall C. Indication-specific pricing of pharmaceuticals in the U.S. health care system: a report from the 2015 ICER Membership Policy Summit. Institute for Clinical and Economic Review. March 2016. Available at: https://icer-review.org/wp-content/uploads/2015/03/Final-Report-2015-ICER-Policy-Summit-on-Indicationspecific-Pricing-March-2016_revised-icons-002.pdf. Accessed August 9, 2017
3. Mestre-Ferrandiz J, Towse A, Dellamano R, Pistollato M. Multi-indication pricing: pros, cons and applicability to the UK. Seminiar Briefing 18. Office of Health Economics. October 2015. Available at: https://www.ohe.org/publications/multi-indication-pricing-pros-cons-and-applicability-uk. Accessed August 9, 2017
4. Kitamura M, Koch J. Express Scripts aims new price model at cancer, inflammation. Bloomberg Business. November 16, 2015. Available at: https://www.bloomberg.com/amp/news/articles/2015-11-16/express-scripts-to-applynew-price-model-to-auto-immune-diseases. Accessed August 9, 2017
5. CVS Health. 2017 formulary strategy. 2016. Available at: https://cvshealth. com/sites/default/files/cvs-health-2017-standard-formulary-list.pdf. Accessed August 9, 2017
6. Barlas S. Health plans and drug companies dip their toes into value-based pricing: the pressure is on P&T committees to monitor utilization. P T. 2016;41(1):39-53
7. Australian Government Department of Health. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.5). Canberra, Australia: Department of Health; 2015. Available at: https://pbac. pbs.gov.au/content/information/printable-files/pbacg-book.pdf. Accessed August 21, 2017
8. Paris V, Belloni A. Value in pharmaceutical pricing. OECD Health Working Papers. No. 63. 2013. Paris: OECD Publishing. Available at: http://dx.doi.org/10.1787/5k43jc9v6knx-en. Accessed August 9, 2017
9. Agenzia Italiana del Farmaco. Lista aggiornata dei Registri e dei Piani Terapeutici. Available at: http://www.agenziafarmaco.gov.it/content/listaaggiornata-dei-registri-e-dei-piani-terapeutici-web-based. Accessed August 21, 2017
10. Bach PB. Alternative pricing strategies for cancer drugs-reply. JAMA. 2015;313(8):858
11. Garrison LP Jr, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703-19
12. Carlson JJ, Garrison LP Jr, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J Manag Care Pharm. 2009;15(8):683-87. Available at: http://www.jmcp.org/doi/10.18553/jmcp.2009.15.8.683
13. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179-90
14. HERCEPTIN (trastuzumab) intravenous infusion. Genentech. Revised March 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103792s5330lbl.pdf. Accessed August 9, 2017
15. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97
16. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92
17. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129(22):2329-45
18. Institute for Clinical and Economic Review. Targeted immune modulators for rheumatoid arthritis: effectiveness & value. Evidence report. April 7, 2017. Available at: https://icer-review.org/wp-content/uploads/2016/08/NE_CEPAC_RA_Evidence:Report_FINAL_040717.pdf. Accessed August 9, 2017
19. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization; 2002. Available at: http://apps.who.int/iris/bitstream/10665/42510/1/WHR_2002.pdf. Accessed August 9, 2017
20. Sullivan SD, Yeung K, Vogeler C, et al. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015;21(4):269-75. Available at: http://www.jmcp.org/doi/10.18553/jmcp.2015.21.4.269
21. Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a value-based formulary on medication utilization, health services utilization, and expenditures. Med Care. 2017;55(2):191-98
22. Yeung K, Basu A, Marcum ZA, Watkins JB, Sullivan SD. Impact of a value-based formulary in three chronic disease cohorts. Am J Manag Care. 2017;23(3 Suppl):S46-S53. Available at: http://www.ajmc.com/journals/supplement/2017/beyond-charitable-assistance-sustainable-strategies-forproviding-access-to-critical-medications/impact-of-a-value-based-formularyin-three-chronic-disease-cohorts/P-1. Accessed August 9, 2017
23. Rugo HS, Brufsky AM, Ulcickas Yood M, et al. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013;141(3):461-70
24. Qiu MZ, Li Q, Wang ZQ, et al. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. Int J Cancer. 2014;134(10):2468-77
25. Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011;105(9):1273-78
26. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a costeffectiveness analysis. J Clin Oncol. 2004;22(5):854-63
27. Centers for Medicare & Medicaid Services. 2016 ASP drug pricing files. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2016ASPFiles.html. Accessed August 21, 2017
28. National Center for Health Statistics. Health, United States, 2015, with special feature on racial and ethnic health disparities. 2016. Available at: https://www.cdc.gov/nchs/data/hus/hus15.pdf. Accessed August 9, 2017
29. Mariotto AB, YabroffKR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28
30. University of Washington School of Pharmacy. Pharmaceutical Outcomes Research & Policy Program. Performance Based Risk Sharing (PBRS) Database. Case database. 2016. Available at: https://depts.washington. edu/pbrs/index.php. Accessed August 9, 2017
31. Stuard S, Beyer J, Bonetto M, et al. State Medicaid alternative reimbursement and purchasing test for high-cost drugs (SMART-D): summary report. Center for Evidence-Based Policy, Oregon Health & Science University. September 2016. Available at: http://smart-d.org/wp-content/uploads/2016/09/SMART-D-Summary-Report-Final.pdf. Accessed August 9, 2017
32. Drummond M. When do performance-based risk-sharing arrangements make sense? Eur J Health Econ. 2015;16(6):569-71
33. Chandra A, Garthwaite C. The economics of indication-based drug pricing. N Engl J Med. 2017;377(2):103-06